— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control — — Fanregratinib holds promise as a new treatment option for pretreated advanced ICC patients harboring FGFR2-fusions/rearrangements — June 25, 2026 -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces results from the pivotal Phase II registration study of fanregratinib (HMPL-453) in patients with intrahepatic cholangiocarcinoma (

June 25, 2026 -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its partner company with Aditum Bio, Oblenio Bio (“Oblenio”), has successfully closed an oversubscribed $62 million Series B financing round. The round was led by Pfizer Ventures, with participation from Deep Track Capital, GV, and founding investor Aditum Bio. This milestone significantly advances the clinical development of LBL‑051, Oblenio’s sole asset – a CD19×BCMA×CD

Study met its primary endpoint, demonstrating statistically significant and clinically relevant improvements in ADHD symptoms in adults with ADHD and comorbid anxiety taking centanafadine compared to those taking placebo Centanafadine is currently under Priority Review by the FDA for the treatment of ADHD in children, adolescents, and adults, with a target action date of July 24, 2026 PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka

June 24, 2026 -- REPROCELL Inc. today announced the submission of an application for manufacturing and marketing approval in Japan for the regenerative medicine product Stemchymal®, for which the company holds exclusive commercialization rights in Japan. The application seeks approval for the use of Stemchymal® to suppress the progression of ataxia in patients with spinocerebellar ataxia (SCA3 and SCA6). Under the established framework, Stemchymal® will be manufactured by Taiwan-based Steminent

Five migraine presentations will showcase Lundbeck's current and future approaches to migraine prevention, including new data for eptinezumab and Phase IIb PROCEED primary data for the investigational treatment, bocunebart Eptinezumab data explore patient-centered outcomes in chronic migraine beyond traditional endpoints, including acute medication use, psychological well-being, and workplace productivity Late breaker bocunebart presentation will provide further insight into pituitary adenylate

LTX-002 is a first-in-class antisense oligonucleotide targeting SPTLC1, designed to restore lipid metabolism in the CNS, a novel approach with the potential to address both sporadic and genetic forms of ALS June 23, 2026 -- Leal Therapeutics, Inc. (Leal), a clinical-stage biopharmaceutical company developing first-in-class neuro-metabolic therapeutics, today announced that the first participant has been dosed in NeurALS, a Phase 1/2 trial of LTX-002 in adults with amyotrophic lateral sclerosis

June 23, 2026 -- Calico Life Sciences LLC (Calico), a clinical-stage biotechnology organization focused on aging and age-related diseases and founded by Alphabet Inc. and Arthur D. Levinson, today announced that the U.S. Food and Drug Administration (FDA) granted fosigotifator Breakthrough Therapy Designation (BTD) for the treatment of Vanishing White Matter (VWM) disease. Fosigotifator, an investigational eIF2B activator, is currently in a Phase 1b/2 clinical trial evaluating its safety, tolera

June 22, 2026 -- NanoGhost Ltd., a biotechnology company developing a proprietary targeted drug delivery platform for cancer and other severe diseases, announced today that it has been awarded a new grant from the Israel Innovation Authority to support an innovative collaborative research program with Ben-Gurion University of the Negev via its technology transfer company, BGN. This marks the sixth grant awarded to NanoGhost by the Israel Innovation Authority, reflecting continued confidence in

June 22, 2026 -- Hamlet BioPharma AB (publ) today announced the signing of a clinical trial agreement with the University of Iowa, one of the leading U.S. centers for bladder cancer research and therapy. The new study advances the clinical development of Alpha1H, a human breast milk derived treatment for bladder cancer, to include Carcinoma In Situ (CIS); a severe surface-spreading and therapy-resistant form of bladder cancer where patients may need to remove their bladders to avoid systemic dis

First-in-class antibody targeting SMOC2 is the third novel anti-fibrotic program to enter the clinic from Mediar's pipeline Phase 1 study will evaluate safety, tolerability, and pharmacokinetics of novel SMOC2-targeting antibody in healthy volunteers and adults with diabetic kidney disease (DKD) Addition of world-renowned CKD experts to the clinical advisory board (CAB) to help advise Phase 2a development in DKD patients Phase 2a programs for systemic sclerosis (SSc) and idiopathic pulmonary fib